Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND

20260 citationsJournal Articlegold Open Access

Authors

Clinicaltrials.gov listing: NCT03587805 (ECZTEND).

Good health and well-being

Published in: Dermatology and Therapy

Volume 16, Issue 4, pp. 2001-2018

Field-Weighted Citation Impact: 0.00